Statins are competitive inhibitors of cholesterol biosynthesis and additional derivatives of the mevalonate pathway. For this cohort study, the investigators conducted a pooled analysis of individual patient data from 2 phase 3 randomized clinical trials that established the role of apalutamide in patients with nmCRPC (SPARTAN) and those with mHSPC (TITAN) to learn if statin exposure associated with overall survival and cardiac adverse events in men with advanced prostate cancer treated with apalutamide.
Learn more here.
